Tissue Reagents PD-L1

 

Contact a Rep HTML

Request more information about PD-L1.

Please complete the form below to speak with a Roche representative.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overview

VENTANA PD-L1 assays identify patients who are most likely to respond to specific therapies and generate results you can trust, so that you can make timely diagnostic decisions and therapeutic choices. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.

PD-L1 assays identify patients who are most likely to respond to specific therapies.

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1 (SP142) Assay gives you the confidence to appropriately identify urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) patients most likely to benefit from TECENTRIQ® (atezolizumab). FDA approved.

Learn more

PD-L1 analytic assays evaluate for expression of PD-L1 in tumor and immune cells in the context of the tumor microenvironment.

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody was the first ready-to-use assay that allowed you to evaluate the expression of PD-L1 protein in tumor and immune cells using the OptiView DAB IHC Detection Kit. Available for sale in the US and CE Marked.

Learn more

Explore

VENTANA PD-L1 (SP142) Assay

PD-L1 assay | Guiding immunotherapy

The VENTANA PD-L1 (SP142) Assay identifies patients most likely to benefit from TECENTRIQ® (atezolizumab). FDA approved.

> Click here for the US testing information

The PD-L1 immunologic checkpoint

Learn more


The tumor microenvironment

Learn more


Non-small cell lung cancer

Using the right test to determine PD-L1 status for immunotherapy options is important, and the VENTANA PD-L1 (SP142) Assay is the only FDA approved test for TECENTRIQ. This innovative assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ.*

The VENTANA PD-L1 (SP142) Assay:

  • FDA approved to assess NSCLC patient treatment benefit from TECENTRIQ
  • Informative for the clinician of a patient’s potential overall survival
  • Novel scoring algorithm using PD-L1 staining in both TC and IC
  • Designed to enhance visual contrast of immune cell staining within the tumor microenvironment

The PD-L1 (SP142) Assay gives you the confidence to guide immunotherapy decisions in NSCLC.

*All randomized patients in a NSCLC phase III study observed benefit from TECENTRIQ regardless of PD-L1 status.


Urothelial carcinoma

Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay* is the first and only FDA approved test predictive for TECENTRIQ in urothelial carcinoma (UC) patients. This novel assay is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

The VENTANA PD-L1 (SP142) Assay:

  • FDA approved to predict UC patient response to TECENTRIQ
  • Designed to enhance visual contrast of immune cell staining within the tumor microenvironment
  • Stains PD-L1 in both tumor cells (TC) and tumor-infiltrating immune cells (IC)

*In the US only available on the VENTANA BenchMark ULTRA Instrument.

VENTANA PD-L1 (SP263)
Rabbit Monoclonal Primary Antibody

PD-L1 analytic assay | Navigating the unknown

The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody was the first ready-to-use IVD IHC antibody that empowered you to evaluate PD-L1 expression using the OptiView DAB IHC Detection Kit. Available for sale in the US and CE Marked.

The PD-L1 immunologic checkpoint

Learn more


The tumor microenvironment

Learn more


PD-L1 diagnostic confidence

VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody* is intended for laboratory use in the detection of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. It is intended to be stained with the VENTANA BenchMark series of immunohistochemical automated slide stainers. It is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types.

*Optimized for use on VENTANA BenchMark instruments. In the US only available on the VENTANA BenchMark ULTRA Instrument.

Contact Us

Outside of Pepper mode, this text will be replaced by the content added in the above "Contact a Rep HTML" code editor.

 
Virtual Slide Box Strategic Resource Center